Open-Label LILAC-2 Data Demonstrates Trofinetide’s Long-Term Treatment Benefit in Rett Syndrome
7 Dec 2023
https://www.neurologylive.com/view/open-label-lilac-2-data-demonstrates-trofinetide-treatment-benefit-32-months
"New open-label data from the LILAC-2 study ...demonstrated the long-term treatment impacts of trofinetide (Daybue; Acadia Pharmacueticals) in patients with Rett syndrome. All told, patients showed continued improved symptoms for up to 32 months, with no new safety signals observed.'
Ann: Positive topline results from Phase 3 trial in Rett syndrome, page-51
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |